Abstract:BackgroundMetformin is a commonly used drug for the treatment of diabetes. Accumulating evidence suggests that it exerts anti-tumor effects in many cancers, including multiple myeloma (MM); however, the underlying molecular mechanisms have not been clearly elucidated.MethodsThe anti-myeloma effects of metformin were evaluated using human MM cell lines (RPMI8226 and U266) in vitro and in vivo NOD-SCID murine xenograft MM model. Cell viability was assessed with CCK8 and cell proliferation was measured by EdU incorporation assay. Cell cycle distribution and apoptosis were examined by flow cytometry. Transmission electron microscopy was used to visualized autophagosomes. Activation of AMPK and inhibition of mTORC1/C2 pathways was assessed by Western blot analysis. RPMI8226 cells and U266 cell lines with AMPK knockdown were generated by transfection with small interfering RNA targeting the AMPK-α1 and α2 subunits using Lipofectamine 2000 reagent.ResultsMetformin effectively inhibited the proliferation of MM cell lines, an effect that was associated with the induction of autophagy and G0/G1 cell cycle arrest, but not apoptosis. Metformin activated AMPK and repressed both mTORC1 and mTORC2 signaling pathways in myeloma cells as well as downstream molecular signaling pathways, such as p-4EBP1 and p-AKT. AMPK activation resulted in direct phosphorylation and activation of tuberous sclerosis complex 2 (TSC2), leading to inhibition of the mammalian target of rapamycin (mTOR). In addition, metformin inhibited myeloma cell growth in an AMPK-dependent manner. The xenograft mouse model further confirmed that metformin inhibited tumor growth by upregulation of AMPK and downregulation of mTOR.ConclusionsMetformin inhibits the proliferation of myeloma cells by inducing autophagy and cell-cycle arrest. Our results suggest that the molecular mechanism involves dual repression of mTORC1 and mTORC2 pathways via AMPK activation. Our study provides a theoretical basis for the development of novel strategies for the treatment of MM using metformin as an already approved and safe drug.

Repurposing Metformin in hematologic tumor: State of art

Action Mechanism of Metformin and Its Application in Hematological Malignancy Treatments: A Review

Preventative and Therapeutic Effects of Metformin in Gastric Cancer: A New Contribution of an Old Friend

Metformin and Cancer Hallmarks: Molecular Mechanisms in Thyroid, Prostate and Head and Neck Cancer Models

Metformin and Malignant Tumors: Not over the Hill

Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing

Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways

Metformin: A Promising Drug for Human Cancers (Review)

Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect

Metformin Displays Anti-Myeloma Activity and Synergistic Effect with Dexamethasone in in Vitro and in Vivo Xenograft Models.

Metformin and Cancer: an Existing Drug for Cancer Prevention and Therapy (Review)

Anticancer mechanisms of metformin: A review of the current evidence

Antitumor Mechanism of Metformin Via Adenosine Monophosphate-activated Protein Kinase (AMPK) Activation

Metformin Inhibits the Function of Granulocytic Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice.

Metabolic Switching in the Hypoglycemic and Antitumor Effects of Metformin on High Glucose Induced HepG2 Cells

The role of the antidiabetic drug metformin in the treatment of endocrine tumors.

Metformin: Current Clinical Applications in Nondiabetic Patients with Cancer

Molecular Mechanisms of Metformin for Diabetes and Cancer Treatment

Harnessing the Soil: Reshaping the Tumor Microenvironment Towards an Antitumor Immune State by Low‐dose Metformin

Metformin: A Novel but Controversial Drug in Cancer Prevention and Treatment

Metformin: From Diabetes to Cancer—Unveiling Molecular Mechanisms and Therapeutic Strategies